Increasing prevalence of respiratory syncytial virus infections worldwide is driving the demand for accurate diagnostics, leading to market growth. Additionally, the adoption of point-of-care testing for quick and efficient diagnosis is also contributing to market expansion. Furthermore, rising awareness among healthcare providers regarding the importance of early detection and treatment of respiratory syncytial virus is expected to drive market growth in the coming years.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Product, End-Use |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Becton, Dickinson, and Company, Novartis AG, Abbott, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Bio-Rad Laboratories,, F. Hoffmann-La Roche., BIOMÉRIEUX, DiaSorin SpA, Merck KGaA, Quidel Corp., Coris BioConcept, Siemens Healthcare SA, Quest Diagnostics |
A major obstacle in the respiratory syncytial virus diagnostics market is the high cost associated with diagnostic tests and equipment. This can limit the accessibility of diagnostics to patients, especially in low-income regions. Another restraint is the lack of skilled healthcare professionals to accurately perform and interpret diagnostic tests, leading to potential misdiagnosis and delayed treatment for patients.